文献速递心脑血管急症重症综合管理与镇静镇痛

促红细胞生成素不改变创伤性脑损伤后血清神经元和轴突生物标志物谱:澳大利亚EPO-TBI临床试验发现

Erythropoietin Does Not Alter Serum Profiles of Neuronal and Axonal Biomarkers After Traumatic Brain Injury: Findings From the Australian EPO-TBI Clinical Trial.
PubMed 文献 · Crit Care Med · 2018-01-01
一句话结论中重度创伤性脑损伤后,皮下注射促红细胞生成素40,000 IU未降低血清UCH-L1和pNF-H浓度,与EPO-TBI试验未见结局改善一致;作者认为所用剂量可能过低。

该研究为EPO-TBI临床试验的单中心前瞻性观察性子研究,在澳大利亚墨尔本阿尔弗雷德医院纳入44例中重度创伤性脑损伤患者,伤后24小时内皮下注射促红细胞生成素α 40,000 IU或0.9%氯化钠1 mL。从D0(伤后24小时内、给药前)至D5连续检测血清泛素羧基末端水解酶L1(UCH-L1)、磷酸化神经丝重链(pNF-H)和促红细胞生成素浓度。UCH-L1在D0达峰值146.0 ng/mL,D1显著降至84.30 ng/mL后继续下降;pNF-H在D0最低,D5达峰值157.9 ng/mL。促红细胞生成素未降低UCH-L1或pNF-H浓度。D3和D4的pNF-H峰值与格拉斯哥结局扩展评分相关,可预测不良结局。

要点

  • 中重度创伤性脑损伤患者伤后24小时内皮下注射促红细胞生成素α 40,000 IU,未降低血清UCH-L1或pNF-H浓度。
  • 血清UCH-L1在D0(伤后24小时内、给药前)达峰值146.0 ng/mL,D1显著降至84.30 ng/mL,此后继续下降。
  • 血清pNF-H在D0最低,D5达峰值157.9 ng/mL,反映进行性轴突损伤。
  • D3和D4的pNF-H峰值与格拉斯哥结局扩展评分相关,可预测不良结局。
  • 作者认为促红细胞生成素的药代动力学提示所用剂量可能过低,不足以发挥神经保护作用。

适用人群与场景

  • 中重度创伤性脑损伤患者44例,来自EPO-TBI临床试验的单中心前瞻性观察性子研究,地点为澳大利亚墨尔本阿尔弗雷德医院。

处置流程与药物剂量

  • 伤后24小时内皮下注射促红细胞生成素α 40,000 IU或0.9%氯化钠1 mL(安慰剂)。
  • 从D0(伤后24小时内、给予促红细胞生成素/溶媒前)至D5,用酶联免疫吸附法检测血清UCH-L1、pNF-H和促红细胞生成素浓度。

研究设计与关键结果

  • 研究类型为单中心前瞻性观察性子研究,样本量44例中重度创伤性脑损伤患者。
  • 干预为促红细胞生成素α 40,000 IU皮下注射,对照为0.9%氯化钠1 mL皮下注射,均在伤后24小时内给药。
  • 血清UCH-L1在D0达峰值146.0 ng/mL,D1显著降至84.30 ng/mL,此后继续下降。
  • 血清pNF-H在D0最低,D5达峰值157.9 ng/mL。
  • D0的UCH-L1浓度在弥漫性创伤性脑损伤中更高。
  • D3和D4的pNF-H峰值与格拉斯哥结局扩展评分相关,可预测不良结局。
  • 促红细胞生成素未降低UCH-L1或pNF-H浓度,生物标志物浓度和变化谱未受促红细胞生成素影响。

证据类型、等级与局限

  • 证据类型:单中心前瞻性观察研究,为EPO-TBI临床试验的子研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,促红细胞生成素的药代动力学提示所用剂量可能过低,不足以发挥神经保护作用;该结果与促红细胞生成素治疗创伤性脑损伤患者未见结局改善一致。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To determine profiles of serum ubiquitin carboxy-terminal hydrolase L1 and phosphorylated neurofilament heavy-chain, examine whether erythropoietin administration reduce their concentrations, and whether biomarkers discriminate between erythropoietin and placebo treatment groups.

DESIGN: Single-center, prospective observational study.

SETTING: A sub-study of the erythropoietin-traumatic brain injury clinical trial, conducted at the Alfred Hospital, Melbourne, Australia.

PATIENTS: Forty-four patients with moderate-to-severe traumatic brain injury.

INTERVENTIONS: Epoetin alfa 40,000 IU or 1 mL sodium chloride 0.9 as subcutaneous injection within 24 hours of traumatic brain injury.

MEASUREMENTS AND MAIN RESULTS: Ubiquitin carboxy-terminal hydrolase L1, phosphorylated neurofilament heavy-chain, and erythropoietin concentrations were measured in serum by enzyme-linked immunosorbent assay from D0 (within 24 hr of injury, prior to erythropoietin/vehicle administration) to D5. Biomarker concentrations were compared between injury severities, diffuse versus focal traumatic brain injury and erythropoietin or placebo treatment groups. Ubiquitin carboxy-terminal hydrolase L1 peaked at 146.0 ng/mL on D0, significantly decreased to 84.30 ng/mL on D1, and declined thereafter. Phosphorylated neurofilament heavy-chain levels were lowest at D0 and peaked on D5 at 157.9 ng/mL. D0 ubiquitin carboxy-terminal hydrolase L1 concentrations were higher in diffuse traumatic brain injury. Peak phosphorylated neurofilament heavy-chain levels on D3 and D4 correlated with Glasgow Outcome Score-Extended, predicting poor outcome. Erythropoietin did not reduce concentrations of ubiquitin carboxy-terminal hydrolase L1 or phosphorylated neurofilament heavy-chain.

CONCLUSIONS: Serum ubiquitin carboxy-terminal hydrolase L1 and phosphorylated neurofilament heavy-chain increase after traumatic brain injury reflecting early neuronal and progressive axonal injury. Consistent with lack of improved outcome in traumatic brain injury patients treated with erythropoietin, biomarker concentrations and profiles were not affected by erythropoietin. Pharmacokinetics of erythropoietin suggest that the dose given was possibly too low to exert neuroprotection.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Hellewell SC, Mondello S, Conquest A, et al. Erythropoietin Does Not Alter Serum Profiles of Neuronal and Axonal Biomarkers After Traumatic Brain Injury: Findings From the Australian EPO-TBI Clinical Trial. Crit Care Med. 2018. PMID: 29278529. doi:10.1097/CCM.0000000000002938

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。